Hospital
Timpanogos Regional Medical Services, INC.
Timpanogos Regional Medical Services, INC. was paid $7.83M by Medicaid between Jan 2018 and Nov 2024, across 95 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 73% of everything it billed.
33Billing provider infoTIMPANOGOS REGIONAL MEDICAL SERVICES, INC.
OREM, UT 84057
OREM, UT 84057
33aNPI1497702195assigned 05/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.83M
24GClaims124,559
24DCodes billed95
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#12 of 26
Median peer was paid$6.14M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,096 | $1.03M | |
| 2019 | 21,595 | $1.12M | |
| 2020 | 20,779 | $1.45M | |
| 2021 | 27,235 | $1.92M | |
| 2022 | 27,671 | $2.04M | |
| 2023 | 4,128 | $167K | |
| 2024incomplete | 2,055 | $102K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 73% | 18,221 | 8,639 | $5.73M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.6% | 9,010 | 7,794 | $285K |
| 80053 | Comprehensive metabolic panel | 3.3% | 6,050 | 5,068 | $258K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.0% | 977 | 835 | $231K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.1% | 4,238 | 3,424 | $164K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.0% | 7,482 | 6,368 | $158K |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 2,119 | 1,905 | $123K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 2,712 | 2,198 | $103K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 2,192 | 1,985 | $99K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,287 | 1,956 | $69K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 555 | 501 | $61K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,925 | 4,921 | $61K |
83 more codes
| 81001 | <1% | 5,420 | $56K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 793 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 583 | $50K |
| 86710 | <1% | 406 | $29K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 753 | $26K |
| 85027 | <1% | 11,701 | $26K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 818 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,518 | $23K |
| 82247 | <1% | 1,175 | $18K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 704 | $17K |
| 99285 | Emergency room visit (most serious) | <1% | 1,364 | $14K |
| J3490 | Unclassified drugs | <1% | 40 | $12K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,118 | $11K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 267 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,015 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 243 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,489 | $7K |
| 87420 | <1% | 123 | $7K | |
| G0378 | Hospital observation service, per hour | <1% | 531 | $7K |
| 87400 | <1% | 199 | $6K | |
| 80306 | <1% | 380 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 68 | $6K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,643 | $5K |
| 74018 | <1% | 96 | $5K | |
| 84484 | <1% | 1,430 | $5K | |
| 84702 | <1% | 646 | $4K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 463 | $4K |
| 80076 | <1% | 1,183 | $4K | |
| 81025 | <1% | 1,299 | $3K | |
| 86140 | <1% | 591 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 341 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,616 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,376 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 15 | $2K |
| 83690 | <1% | 1,859 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 959 | $1K |
| 73610 | <1% | 14 | $1K | |
| 80061 | Lipid panel | <1% | 269 | $1K |
| 82565 | <1% | 257 | $1K | |
| 73630 | <1% | 13 | $904.29 | |
| 82947 | <1% | 58 | $870.03 | |
| 94760 | <1% | 108 | $679.65 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 299 | $604.36 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 218 | $577.13 |
| 87186 | <1% | 383 | $577.10 | |
| 86900 | <1% | 209 | $438.97 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 15 | $427.40 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 397 | $412.79 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,231 | $339.42 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 839 | $317.70 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $265.70 |
| 73030 | <1% | 15 | $156.22 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 65 | $150.44 |
| 84439 | <1% | 117 | $138.31 | |
| 84703 | <1% | 403 | $137.27 | |
| 81003 | <1% | 18 | $122.51 | |
| 99152 | <1% | 79 | $119.71 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,087 | $116.21 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 109 | $115.98 |
| 85652 | <1% | 149 | $78.33 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51 | $49.16 |
| 85007 | <1% | 101 | $47.50 | |
| 87040 | <1% | 172 | $39.13 | |
| 83735 | <1% | 381 | $16.85 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 547 | $12.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 140 | $5.59 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 708 | $0.00 |
| 85610 | 0% | 187 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 135 | $0.00 |
| 86901 | 0% | 209 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 98 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 298 | $0.00 |
| 96376 | 0% | 437 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 27 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 165 | $0.00 |
| 83605 | 0% | 164 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 143 | $0.00 |
| 85379 | 0% | 24 | $0.00 | |
| 86850 | 0% | 96 | $0.00 | |
| 36000 | 0% | 18 | $0.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 36 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 44 | $0.00 |
| A9270 | Non-covered item or service | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSQUIRES, STEVE (CFO)